ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.732,53
-0,13%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07813
0,10%
Bitcoin
62.587,93
1,86%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Dyne Therapeutics Inc (DYN)

  7. Dyne Therapeutics Inc (DYN) News

DYN Dyne Therapeutics Inc

26,00
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:05:15
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Dyne Therapeutics Inc DYN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 26,00 10:05:15
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
26,00
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202422:10GLOBEDyne Therapeutics Reports First Quarter 2024 Financial..
27.3.202421:05GLOBEDyne Therapeutics Reports Inducement Grant Under Nasdaq..
27.3.202413:30GLOBEDyne Therapeutics to Present at the Cantor Virtual Muscular..
25.3.202412:30GLOBEDyne Therapeutics Announces CEO Transition
13.3.202412:30GLOBEDyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
11.3.202422:36EDGAR2Form 144 - Report of proposed sale of securities
11.3.202422:35EDGAR2Form 144 - Report of proposed sale of securities
11.3.202422:35EDGAR2Form 144 - Report of proposed sale of securities
08.3.202422:53EDGAR2Form 144 - Report of proposed sale of securities
08.3.202402:19EDGAR2Form 144 - Report of proposed sale of securities
08.3.202402:18EDGAR2Form 144 - Report of proposed sale of securities
08.3.202402:16EDGAR2Form 144 - Report of proposed sale of securities
05.3.202414:22EDGAR2Form S-3ASR - Automatic shelf registration statement of..
05.3.202413:41EDGAR2Form 8-K - Current report
05.3.202413:40EDGAR2Form S-8 - Securities to be offered to employees in employee..
05.3.202413:35EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05.3.202413:30GLOBEDyne Therapeutics Reports Fourth Quarter and Full Year 2023..
02.3.202403:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.3.202403:33EDGAR2Form 144 - Report of proposed sale of securities
01.3.202423:08EDGAR2Form 144 - Report of proposed sale of securities
01.3.202401:49EDGAR2Form 144 - Report of proposed sale of securities
23.2.202423:23EDGAR2Form 144 - Report of proposed sale of securities
14.2.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:15GLOBEDyne Therapeutics Announces Upcoming Presentations on..
14.2.202414:39EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12.2.202423:40EDGAR2Form 144 - Report of proposed sale of securities
01.2.202413:30GLOBEDyne Therapeutics to Present at February Investor..
27.1.202401:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.1.202401:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.1.202401:46EDGAR2Form 144 - Report of proposed sale of securities
11.1.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.1.202422:05GLOBEDyne Therapeutics Announces Closing of Public Offering of..
05.1.202422:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05.1.202414:02EDGAR2Form 8-K - Current report
05.1.202413:30GLOBEDyne Therapeutics to Present at 42nd Annual J.P. Morgan..
05.1.202404:46GLOBEDyne Therapeutics Announces Pricing of $300 Million Public..
05.1.202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202403:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202403:45EDGAR2Form 144 - Report of proposed sale of securities
05.1.202403:45EDGAR2Form 144 - Report of proposed sale of securities
05.1.202403:19EDGAR2Form S-3MEF - Registration adding securities to prior Form..
04.1.202423:12EDGAR2Form 8-K - Current report
04.1.202402:14EDGAR2Form 144 - Report of proposed sale of securities
04.1.202402:12EDGAR2Form 144 - Report of proposed sale of securities
03.1.202422:37EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03.1.202422:25GLOBEDyne Therapeutics Announces Proposed Public Offering of..
03.1.202412:37EDGAR2Form 8-K - Current report
03.1.202412:30GLOBEDyne Therapeutics Announces Positive Initial Clinical Data..
02.1.202422:05GLOBEDyne Therapeutics to Host Virtual Event Tomorrow, January 3..
30.12.202303:03EDGAR2Form 144 - Report of proposed sale of securities

Kürzlich von Ihnen besucht

NASDAQ
DYN
Dyne Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten